These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31586229)

  • 21. Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Head Neck; 2015 May; 37(5):670-6. PubMed ID: 24596112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma.
    Arias F; Asín G; Uzcanga MI; Maraví E; Quílez I; Chicata V; Eito C; Viudez A; Hernández I; Mañeru F; Domínguez MA
    Clin Transl Oncol; 2014 Jun; 16(6):555-60. PubMed ID: 24203760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
    Finnegan V; Parsons JT; Greene BD; Sharma V
    Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone.
    Jeremic B; Shibamoto Y; Milicic B; Dagovic A; Nikolic N; Aleksandrovic J; Acimovic L; Milisavljevic S
    Lung Cancer; 2003 Jun; 40(3):317-23. PubMed ID: 12781431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H; Tsukuda M; Watai K
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model.
    Strigari L; Pinnarò P; Carlini P; Torino F; Strolin S; Minosse S; Sanguineti G; Benassi M
    Crit Rev Oncol Hematol; 2016 Jun; 102():101-10. PubMed ID: 27157527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.
    Dornoff N; Weiß C; Rödel F; Wagenblast J; Ghanaati S; Atefeh N; Rödel C; Balermpas P
    Strahlenther Onkol; 2015 Aug; 191(8):656-64. PubMed ID: 26004121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
    Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
    Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
    Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
    Ghosh-Laskar S; Kalyani N; Gupta T; Budrukkar A; Murthy V; Sengar M; Chaukar D; Pai P; Chaturvedi P; D'Cruz A; Agarwal J
    Head Neck; 2016 Feb; 38(2):202-7. PubMed ID: 25224814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
    Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
    Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
    Jeremić B; Miličić B; Milisavljević S
    Clin Transl Oncol; 2013 Sep; 15(9):747-53. PubMed ID: 23359170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer.
    Nguyen NP; Vock J; Chi A; Vinh-Hung V; Dutta S; Ewell L; Jang S; Betz M; Almeida F; Miller M; Davis R; Sroka T; Vo RP; Karlsson U; Vos P
    Strahlenther Onkol; 2012 Aug; 188(8):677-83. PubMed ID: 22659942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
    Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
    Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.